MG
RIGL icon

Meditor Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Meditor Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-90,000
Closed -$3.01M – 41
2013
Q2 		$3.01M Buy
+90,000
New +$4.08M 0.41% 33

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Meditor Group's RIGL Position: Q3 2013 in Review

Meditor Group sold out of Rigel Pharmaceuticals (RIGL) in Q3 2013, closing a stake of 90,000 shares — an estimated $3.01M sold.

Meditor Group first reported a position in RIGL in Q2 2013 and held it in 1 quarter. The position peaked at $3.01M in Q2 2013. 95 funds tracked by Wall St. Rank hold RIGL as of Q3 2013.

  • Meditor Group reported no remaining Rigel Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Meditor Group sold 90,000 Rigel Pharmaceuticals shares in Q3 2013, an estimated $3.01M.
  • Meditor Group first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Meditor Group's Rigel Pharmaceuticals position peaked at $3.01M in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2013.

Based on Meditor Group's 13F filing for Q3 2013, filed 25 Oct 2013.